BACKGROUND: Comprehensive analyses of host, viral, and immune factors associated with severe respiratory syncytial virus (RSV) infection in adults have not been performed. METHODS: Adults with RSV infection identified in both outpatient and inpatient settings were evaluated. Upper and lower respiratory tract virus load, duration of virus shedding, select mucosal chemokine and cytokine levels, humoral and mucosal immunoglobulin responses, and systemic T-cell responses were measured. RESULTS: A total of 111 RSV-infected adults (61 outpatients and 50 hospitalized patients) were evaluated. Hospitalized subjects shed virus in nasal secretions at higher titers and for longer durations than less ill outpatients, had greater mucosal interleukin 6 (IL-6) levels throughout infection, and had higher macrophage inflammatory protein 1α (MIP-1α) levels early in infection. Persons >64 years old and those with more severe disease had a higher frequency of activated T cells in the blood than younger, less ill subjects at infection. Multivariate analysis found that the presence of underlying medical conditions, female sex, increased mucosal IL-6 level, and longer duration of virus shedding were associated with severe disease. Older age and increased nasal MIP-1α levels were of borderline statistical significance. CONCLUSIONS: Multiple factors, but not older age, are independently associated with severe RSV infection in adults. The presence of underlying medical conditions had the greatest influence on disease severity.
BACKGROUND: Comprehensive analyses of host, viral, and immune factors associated with severe respiratory syncytial virus (RSV) infection in adults have not been performed. METHODS: Adults with RSV infection identified in both outpatient and inpatient settings were evaluated. Upper and lower respiratory tract virus load, duration of virus shedding, select mucosal chemokine and cytokine levels, humoral and mucosal immunoglobulin responses, and systemic T-cell responses were measured. RESULTS: A total of 111 RSV-infected adults (61 outpatients and 50 hospitalized patients) were evaluated. Hospitalized subjects shed virus in nasal secretions at higher titers and for longer durations than less ill outpatients, had greater mucosal interleukin 6 (IL-6) levels throughout infection, and had higher macrophage inflammatory protein 1α (MIP-1α) levels early in infection. Persons >64 years old and those with more severe disease had a higher frequency of activated T cells in the blood than younger, less ill subjects at infection. Multivariate analysis found that the presence of underlying medical conditions, female sex, increased mucosal IL-6 level, and longer duration of virus shedding were associated with severe disease. Older age and increased nasal MIP-1α levels were of borderline statistical significance. CONCLUSIONS: Multiple factors, but not older age, are independently associated with severe RSV infection in adults. The presence of underlying medical conditions had the greatest influence on disease severity.
Authors: F Eun-Hyung Lee; Edward E Walsh; Ann R Falsey; Nathaniel Liu; Dacheng Liu; Anagha Divekar; Jennifer E Snyder-Cappione; Tim R Mosmann Journal: Mech Ageing Dev Date: 2005-11 Impact factor: 5.432
Authors: Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp Journal: J Virol Date: 2009-10-28 Impact factor: 5.103
Authors: Caroline M Percopo; Michelle Ma; Todd A Brenner; Julia O Krumholz; Timothy J Break; Karen Laky; Helene F Rosenberg Journal: J Immunol Date: 2018-12-21 Impact factor: 5.422
Authors: Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett Journal: NPJ Vaccines Date: 2020-02-14 Impact factor: 7.344
Authors: D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh Journal: J Infect Dis Date: 2018-07-02 Impact factor: 5.226
Authors: Teun Guichelaar; Jeroen Hoeboer; Myra N Widjojoatmodjo; Sylvia S N Reemers; Cécile A C M van Els; Rob Otten; Yvonne van Remmerden; Jolande Boes; Willem Luytjes Journal: J Virol Date: 2014-06-11 Impact factor: 5.103
Authors: Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther Journal: Hum Vaccin Immunother Date: 2020-10-29 Impact factor: 3.452
Authors: Elisa H Fleming; Eliana E Ochoa; Joan E Nichols; M Kerry O'Banion; Alan R Salkind; Norbert J Roberts Journal: J Med Virol Date: 2017-09-26 Impact factor: 2.327